- Decision Biomarkers awarded patent for protein arraysurface chemistry.
Decision Biomarkers, Inc. (Waltham, MA), a leading developer of protein biomarker analysis systems for pharmaceutical research and development, announced the company's PATH technology has been awarded United States Patent 7,297,497 by the United States Patent and Trademark Office. The patent applies to a novel, ultra-thin nitrocellulose surface chemistry that enables ......
- Protein array systems proliferate.
With the prominence of proteomics and the scientific and commercial success of DNA microarrays has come the promise of protein microarrays. But for all the publicity, investments and development time devoted to this technology, the market for protein microarrays (protein arrays) has been slow to develop. The most conspicuous format ......
- SRU Biosystems denies optical patent infringement
claim.
SRU Biosystems, Inc. (Woburn, MA) announced they see no merit to the patent infringement lawsuit filed on July 10, 2003 by Corning, Inc. and Artificial Sensing Instruments AG. The suit alleges that SRU Biosystems infringes ASI's United States Patent 4,815,843 which has been licensed exclusively by ASI to Corning. SRU ......
- Genomic Solutions validates protein chip
system.
Genomic Solutions, Inc. (Ann Arbor, MI; 734-975-4800) announced that its internal proteomics research and development team has successfully validated the use of its GeneTAC HybStation, G3, LS IV and UC4 instruments for protein chip production, processing, imaging and analysis. According to John D'Errico, Ph.D., Genomics Global Product Manager, "This new ......
- Nastech acquires rights to obesity hormone nasal
administration from Thiakis.
Nastech Pharmaceutical Company, Inc. (Bothell, WA) has acquired exclusive worldwide rights to the Imperial College Innovations and Oregon Health & Science University (Portland, OR) PYY patent applications in the field of intranasal delivery of PYY and the use of glucagon-like peptide-1 (GLP-1) used in conjunction with PYY for the treatment ......
- Nastech acquires Cedars-Sinai Medical Center patent
estate for treatment of obesity.
Nastech Pharmaceutical Company Inc. (Bothell, WA) announced today it has acquired exclusive worldwide rights to the Cedars-Sinai Medical Center (Los Angeles, CA) (CSMC) Peptide YY patent , patent applications, and proprietary know-how estate to support ongoing commercialization efforts of Nastech's investigational PYY 3-36 Nasal Spray for Obesity. Peptide YY is ......
- Nastech acquires exclusive worldwide rights to peptide
YY analog patents and patent applications from University of
Cincinnati.
Nastech Pharmaceutical Company, Inc. (Bothell, WA) has acquired exclusive worldwide rights to patents and patent applications from the University of Cincinnati (Cincinnati, OH) covering analogs of Peptide YY, or peptide derivatives, in the fields of obesity, appetite suppression, reducing food intake, inducing weight loss and inducing satiety. The agreement includes ......
Print
Email
Digg It
del.icio.us